Linked Life Data

19782109

Source:http://linkedlifedata.com/resource/pubmed/id/19782109

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
16
pubmed:dateCreated
2010-3-29
pubmed:abstractText
As history has demonstrated, post-approval obstacles can impede a vaccine's use and potentially lead to its withdrawal. Addressing these potential obstacles when changes in a vaccine's technology can still be easily made may improve a vaccine's chances of success. Augmented vaccine target product profiles (TPPs) can help vaccine scientists better understand and anticipate these obstacles and galvanize conversations among various vaccine stakeholders (e.g., scientists, marketers, business development managers, policy makers, public health officials, health care workers, third party payors, etc.) earlier in a vaccine's development.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Apr
pubmed:issn
1873-2518
pubmed:author
pubmed:copyrightInfo
(c) 2009 Elsevier Ltd. All rights reserved.
pubmed:issnType
Electronic
pubmed:day
1
pubmed:volume
28
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
2806-9
pubmed:meshHeading
pubmed:year
2010
pubmed:articleTitle
Constructing target product profiles (TPPs) to help vaccines overcome post-approval obstacles.
pubmed:affiliation
School of Medicine, University of Pittsburgh, Pittsburgh, PA 15213, USA. BYL1@pitt.edu
pubmed:publicationType
Journal Article, Review, Research Support, Non-U.S. Gov't